Havrix Junior (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix Junior is indicated for active immunisation against hepatitis A virus in children.

• Primary prevention of hepatitis A infection in children aged 1 year and older.
• Use in routine childhood vaccination programmes where hepatitis A risk is recognised.
• Administration to children who have not previously received hepatitis A vaccine.
• May be given to children travelling to regions with high hepatitis A endemicity.
• Can be used in outbreak control settings to protect susceptible paediatric populations.

The safety profile of Havrix Junior reflects the typical reactions observed with inactivated viral vaccines.

Common

• Mild pain, redness or swelling at the injection site.
• Low‑grade fever.
• Headache.
• Fatigue.

Serious

• Allergic reactions such as urticaria, angioedema or anaphylaxis.
• Rare neurologic events (e.g., Guillain‑Barré syndrome).
• Persistent high fever.

Precautions for Havrix Junior focus on patient history, immune status and proper administration technique.

• Assess for severe allergic reaction to any component, especially algeldrate.
• Defer vaccination in individuals with acute moderate or severe illness.
• Use caution in immunocompromised children; vaccine may be less effective.
• Post‑vaccination, monitor for signs of anaphylaxis for at least 15 minutes.
• Do not administer intravascularly; ensure correct intramuscular route.
• Pregnancy and breastfeeding status should be discussed with a healthcare professional.

Havrix Junior has limited documented drug interactions, but certain substances may affect immune response or increase adverse‑event risk.

Avoid

• Live viral vaccines administered within 4 weeks before or after Havrix Junior.
• Immunoglobulin or blood products given within 2 weeks of vaccination, which may reduce antibody response.

Use with caution

• Immunosuppressive therapies (e.g., corticosteroids) that could diminish vaccine efficacy.
• Antipyretics taken prophylactically may mask low‑grade fever.
• Chronic medical conditions requiring ongoing medication should be reviewed by a clinician.